August 1, 1999Microbiology and Immunology

Protective Immune Response to 16 kDa Immunoreactive Recombinant Protein Encoding the C‐Terminal VP1 Portion of Foot and Mouth Disease Virus Type Asia 1

View Full Paper

Ask AI

Bookmark

Structured PICO

Population

Guinea pigs

Intervention

Recombinant protein of FMDV type Asia 1 (C-terminal half of VP1) 40 microg/animal primary dose and booster at 21 days, with various adjuvants (ISCOMs, Montanide ISA 206, FIA, LPS, cytokine mixture)

Outcome

Humoral response (ELISA and SNT titers) and protection against challenge virus at 105 days post-vaccinationsurrogate

A recombinant C-terminal VP1 protein vaccine provides protective immunity against FMDV type Asia 1 in guinea pigs.

Discussion

No takes yet. Share an insight, caveat, or question.

Implication

Demonstrates durable protection in guinea pigs; leaves open translation to livestock and field efficacy trials.

Cite This Study

Bayry et al. (1999) studied this question.

synapsesocial.com/papers/6a9544736f34f99aa233130e https://doi.org/10.1111/j.1348-0421.1999.tb02468.x

View Full Paper

Ask AI

Bookmark

Protective Immune Response to 16 kDa Immunoreactive Recombinant Protein Encoding the C‐Terminal VP1 Portion of Foot and Mouth Disease Virus Type Asia 1

Structured PICO

Discussion

Implication

Cite This Study

Protective Immune Response to 16 kDa Immunoreactive Recombinant Protein Encoding the C‐Terminal VP1 Portion of Foot and Mouth Disease Virus Type Asia 1

Structured PICO

Discussion

Implication

Cite This Study

Also Consider

Also Consider